Comanche Biopharma

Founded 2020 · Biotech · Private

Therapeutic targeting endothelial dysfunction in preeclampsia pathogenesis

Claim this profile

Follows are private to you and power your alerts

Updated · comanchebiopharma.com

Sector
Biotech
Founded
2020
Latest Form D
$37.5M, Jan 2024
Total capital
$73.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$73.6M
2 Form D · last Jan 2024
33 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

20232024FEDERAL ↑EQUITY ↓Cumulative $73.6M1st Form D$36.1M2nd Form D$37.5M
20232024FEDERAL ↑EQUITY ↓Cumulative $73.6M1st Form D$36.1M2nd Form D$37.5M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$37.5M
  • Private capital raisedForm D · SEC · 1st filing$36.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Allison AugustExecutive OfficerNamed in SEC Form D filings
  • Allyson FelixDirectorNamed in SEC Form D filings
  • Ann Scott TaylorDirectorNamed in SEC Form D filings
  • Arthur Scott LevinDirectorNamed in SEC Form D filings
  • Brendan Bulik-SullivanDirectorNamed in SEC Form D filings
  • Clive Scott MeanwellDirectorNamed in SEC Form D filings
Show all 14 people
  • David GrayzelDirectorNamed in SEC Form D filings
  • Ketan PatelDirectorNamed in SEC Form D filings
  • Michael YoungExecutive OfficerNamed in SEC Form D filings
  • Muzammil Scott MansuriDirectorNamed in SEC Form D filings
  • Paul Scott AntinoriExecutive OfficerNamed in SEC Form D filings
  • Scott GottliebDirectorNamed in SEC Form D filings
  • Thomas Scott JohnsonExecutive Officer, DirectorNamed in SEC Form D filings
  • Thomas Scott JohnsonExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 2
  • PendingFormulations Of Nucleic Acid Compounds And Uses ThereofUSPTOApplication PCTUS2024037635
  • PendingFormulations Of Nucleic Acid Compounds And Uses ThereofUSPTOApplication 63513429
  • Aurion Biotech, Inc.Similar federal contract value in Biotech · null in contracts
  • Larimar TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Nocion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Expansion TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • SepternaSimilar federal contract value in Biotech · null in contracts
  • Blueprint MedicinesSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .